American Society of Hematology

The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.

Blood

Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.

Blood Advances

Blood Advances, the first journal to join the Blood family in 70 years, is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, the inaugural issue made it's debut in December at the 58th ASH Annual Meeting and Exposition in San Diego.

Research Programs and Awards

Explore programs offered by ASH to support clinical and scientific hematology research

Hematology Research Agenda

ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community

View all Diffusion articles
  • ACA Update

    The House of Representatives released legislation, titled the “American Health Care Act,” to repeal the Affordable Care Act.  As written, ASH has serious concerns that this legislation will reduce overall access to coverage and treatment and would greatly impact patients with hematologic diseases and disorders.

  • DEA Eliminates Grace Period for Registration Renewal

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

View all policy news
back to top